# DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)

> **NCT06539195** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 59 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** DZD8586
- **DRUG:** DZD8586
- **DRUG:** DZD8586

## Key facts

- **NCT ID:** NCT06539195
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-13
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06539195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06539195, "DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06539195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*